INSMED Inc (NASDAQ: INSM)

INSMED Inc is a global biopharmaceutical company focused on discovering developing and commercializing therapies for patients with serious diseases. The company concentrates its efforts in three therapeutic areas: respiratory immunology and inflammation and neuro and other rare. Its approach combines internal research with in licensing and acquisition activities to build a portfolio of approved medicines and investigational candidates.

INSMED generates revenue primarily from the sale of its two approved products ARIKAYCE and BRINSUPRI. ARIKAYCE is an inhaled antibiotic used to treat nontuberculous mycobacterial lung disease caused by MAC. BRINSUPRI is an oral tablet indicated for non cystic fibrosis bronchiectasis. Revenue is derived from product sales to wholesalers distributors and specialty pharmacies in the United States Europe and Japan. The company also may receive milestone payments and royalties from licensing agreements but its core revenue stream comes from product sales.

The company operates through the following segments: Respiratory, Immunology & Inflammation, and Neuro & Other Rare.

• The Respiratory segment includes the approved products ARIKAYCE for MAC lung disease and BRINSUPRI for bronchiectasis. It also contains pipeline candidates such as TPIP an inhaled dry powder formulation being studied for pulmonary hypertension associated with interstitial lung disease pulmonary arterial hypertension progressive pulmonary fibrosis and idiopathic pulmonary fibrosis and INS1148 a monoclonal antibody targeting a specific isoform of Stem Cell Factor.

• The Immunology & Inflammation segment focuses on the development of brensocatib a small molecule inhibitor of dipeptidyl peptidase 1 for the treatment of hidradenitis suppurativa and other inflammatory conditions.

• The Neuro & Other Rare segment consists of gene therapy programs including INS1201 an intrathecally delivered treatment for Duchenne muscular dystrophy and INS1202 an intrathecally delivered therapy aimed at patients with amyotrophic lateral sclerosis.

INSMED occupies a niche position in the biopharmaceutical industry by concentrating on rare and serious diseases where few approved therapies exist. Its competitive advantages include proprietary drug delivery technologies such as the Pulmovance liposomal platform for ARIKAYCE and novel mechanisms of action like the DPP1 inhibition of brensocatib. The company has secured orphan drug designations in multiple jurisdictions which provide periods of market exclusivity and reduce direct competition for its approved indications.

INSMED serves patients diagnosed with rare lung diseases immunologic disorders and neurologic conditions. Its customers include hospitals specialty clinics and healthcare providers who prescribe ARIKAYCE and BRINSUPRI to eligible patients. The company also works with wholesalers and specialty pharmacies that distribute its products in the United States Europe and Japan.